A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes

Summary

The purpose of this clinical study is to find out how the novel insulin NNC0363-1063 and a non-glucose carbohydrate used in food and beverage might interact in participants with type 1 diabetes and if co-administration of these substances is safe and tolerable. All participants will get a fixed dose of NNC0363-1063 and an oral administration of different amounts of the non-glucose carbohydrate in a random order during 4 interaction tests. The participants will be in this clinical study for about 5 to 12 weeks.

Timeline

Start

2025-12-16

Primary completion

2026-04-21

Completion

2026-05-08

Drugs

Indications